<DOC>
	<DOC>NCT00662116</DOC>
	<brief_summary>This study is being done to evaluate the safety and effectiveness of alagebrium in subjects diagnosed with diastolic heart failure. The primary assessment for effectiveness is the assessment of exercise tolerance.</brief_summary>
	<brief_title>Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure, Diastolic</mesh_term>
	<criteria>diagnosis of diabetes or hypertension requiring therapy EF &gt;/= 45% via echo within 1 year and evidence of diastolic heart failure via echo measurement of E/E'&gt;/= 12 determined by echo within 1 year previous hospitalization for heart failure or previous BNP &gt;100 pg/mL. Clinically significant valvular disease history of stroke/TIA or reversible ischemic neurological defect w/i 6 mths history of acute MI within 6 months severe COPD active or treated malignancies (except basal cell carcinoma) significant systemic illnesses that would prohibit completion of the study or compliance</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>diastolic heart failure</keyword>
</DOC>